Catalyst Pharma neurology news

Catalyst disclosed in its 4Q12 earnings that it will require a strategic partner or grant funding for the "near-term advancement" of GABA transaminase inhibitor CPP-115 to treat West syndrome (infantile spasms). Last year, Catalyst reported that single ascending-doses of 5-500 mg oral CPP-115 were well tolerated in a Phase Ia trial in healthy volunteers. CPP-115 has Orphan Drug designation in the U.S. and EU for West Syndrome and Fast Track designation in the U.S. for cocaine addiction. As of Dec. 31, 2012, Catalyst had $15.4 million in cash and a 2012 operating loss of $5.2 million (see BioCentury, June 4, 2012). ...